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BRCA1-associated protein-1 (BAP1) mutations cause a new cancer syndrome, with a high rate of malignant mesothelioma (MM).
Here, we tested the hypothesis that MM associated with germline
BAP1 mutations has a better prognosis compared with sporadic
MM. We compared survival among germline BAP1 mutation MM
patients with that of all MM (N = 10 556) recorded in the United
States Surveillance, Epidemiology, and End Results (SEER) data
from 1973 to 2010. We identified 23 MM patients—11 alive—with
germline BAP1 mutations and available data on survival. Ten
patients had peritoneal MM, ten pleural MM and three MM in
both locations. Thirteen patients had one or more malignancies in
addition to MM. Actuarial median survival for the MM patients
with germline BAP1 mutations was 5 years, as compared with
<1 year for the median survival in the United States SEER MM
group. Five-year survival was 47%, 95% confidence interval (24–
67%), as compared with 6.7% (6.2–7.3%) in the control SEER
group. Analysis of the pooled cohort of germline BAP1 mutation
MM showed that patients with peritoneal MM (median survival
of 10 years, P = 0.0571), or with a second malignancy in addition to MM (median survival of 10 years, P = 0.0716), survived
for a longer time compared with patients who only had pleural
MM, or MM patients without a second malignancy, respectively.
In conclusion, we found that MM patients with germline BAP1
mutations have an overall 7-fold increased long-term survival,
independently of sex and age. Appropriate genetic counseling and
clinical management should be considered for MM patients who
are also BAP1 mutation carriers.

Introduction
Malignant mesothelioma (MM) is a devastating and lethal cancer associated with exposure to mineral fibers. It arises from the
mesothelial cells of the pleura (80–90%), peritoneum (10–15%)
and more rarely pericardium (<5%) (1). MM is rare: annually ~1–2
cases are diagnosed per million inhabitants in countries without
significant use of asbestos (1). In the USA the incidence of MM
varies from 5.8 to 16.5 cases per million inhabitants, depending
on the extent of commercial asbestos use and the presence of natural mineral deposits (2). Although MM incidence was predicted to
decrease following the ban of asbestos (1,3), it is still increasing
Abbreviations: BAP1, BRCA1-associated protein-1; CI, confidence interval;
MM, malignant mesothelioma; SEER, Surveillance, Epidemiology, and End
Results.

worldwide (4), and it has remained stable at ~3200 cases/year in the
USA since 2003 (2). There are several reasons that may account for
the persistent increase or at least lack of reduction of MM worldwide and in the USA, respectively. Worldwide, the use of asbestos
continues to increase, especially in developing countries (5). In
Europe and in the USA the ban on asbestos has eliminated or drastically reduced its use; however, asbestos is a very durable material,
which is the very reason it has been used so extensively. Therefore,
millions of tons of asbestos that have been used during the past
decades remain in place and continue to pose a risk to millions of
people. In other words, although the amount of occupational exposure has diminished, the number of people exposed to low amounts
of asbestos or other carcinogenic fibers has increased. For example,
it has been estimated that over 20 million homes in the USA contain
asbestos or have roofs made of asbestos (6). As times passes, asbestos deteriorates and the risk of exposure to asbestos dust increases.
In addition, asbestos is a commercial name that was given to six
mineral fibers because they were used commercially from the mid19th century (5). There are, however, ~400 additional mineral fibers in nature, and although these fibers are not called ‘asbestos’
their potential to induce MM is similar to the six fibers that were
included in the ‘asbestos’ definition. Erionite, antigorite, winchite
and richterite are four of such fibers that have been shown to cause
MM (5). As rural areas in the USA and in Europe are developed,
the likelihood of human exposure to such fibers increases, as documented, for example in North Dakota (USA) for erionite, New
Caledonia for antigorite and Libby Montana (USA) for winchite
and richterite (5). Together, asbestos in place, increased exposure
to other types of carcinogenic mineral fibers, inherited mutations
of the BRCA1-associated protein-1 (BAP1) gene (7), and possible
additional causes that at this time are not yet defined, likely account
for the continued high incidence of MM.
MM occurs after a median latency period of 30–50 years from
initial exposure to mineral fibers (8). The mean age at diagnosis is
70–74 years (1) and due to occupational exposure the male to female
sex ratio is generally 4:1–8:1 (9). Because the diagnosis is often made
at a late stage, MM prognosis is very poor, with a median survival
of 6–12 months and a 5-year survival of <5% (10). Epithelial MM
is the most common histological subtype and is associated with better survival (11.1 months) than other subtypes, as follows: sarcomatoid (4.5 months), biphasic (7.2 months) and undifferentiated MM
(2.7 months) (11,12). Women have a better survival compared with
men, independent of age, stage and treatment (13).
Occupational exposure to asbestos appears to account for ~50–80%
of male and ~15–20% of female MM cases (14). Actually, environmental exposure to mineral fibers present in the natural environment
poses a risk similar to occupational exposure to asbestos (5). Recently,
we discovered that germline mutations of the BAP1 gene cause a
hereditary cancer syndrome characterized by a very high incidence
of MM and uveal melanoma in families that were not occupationally
exposed to asbestos (7,15). Several other studies have confirmed and
expanded our findings (16–31).
BAP1 is a nuclear deubiquitinylase and is usually found as part
of multiprotein complexes that regulate key cellular pathways,
including the cell cycle, cellular differentiation, cell death, gluconeogenesis and the DNA damage response. BAP1 is located on
chromosome 3p21 in a region that often shows loss or deletion in
various cancers (7).
We have been studying two families with germline BAP1 mutations
for over 10 years (7). Several family members developed MM, and we
noted that some of them had prolonged survival. Thus, in this study
we tested the hypothesis that MM occurring in germline BAP1 mutation carriers (hereafter referred to as ‘BAP1 MM cohort’) has a better
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survival compared with sporadic MM. This is the first study of MM
survival among patients with germline BAP1 mutation.
Materials and methods
A systematic search of the PubMed databases was conducted to identify all
appropriate family studies on germline BAP1 mutations for pooled analysis
inclusion, using the search terms ‘germline’ and ‘BAP1’, or ‘family’ and
‘BAP1’. The inclusion criteria were (i) family studies on BAP1, (ii) one positive germline BAP1 mutation found in at least one member of the family, (iii)
MM diagnosed in at least one member of the family. Predefined exclusion
criteria were assigned for studies that did not include the minimal information:
BAP1 status, age at diagnosis, gender, age at death or status at end of followup, site of MM. If any of this information was missing the MM case was not
included in our study. Eighteen papers were initially selected (15,17–25,27–
34), and four of them satisfied the inclusion and exclusion criteria, with a total
of six selected families (15,18–20) (Table I).
Twenty-three germline BAP1 mutation carrier MM patients were identified
aged 34–87 years old that met the inclusion and exclusion criteria (see above).
Sixteen of them were from families we are studying: 10 from two BAP1 families we studied for many years (15); and six were from six separate families
that we screened recently because of a history of MM and other malignancies.
In these 16 MM patients, BAP1 mutation status was assessed by extracting
genomic DNA from whole blood followed by bidirectional sequencing of the
BAP1 gene (15). Seven additional MM that developed in germline BAP1 mutation carriers were from four families that were published by others; the details
of genetic testing are described in those publications (17–20).
The population-based comparison group was of all MM cases recorded
at the Surveillance, Epidemiology, and End Results (SEER) program from
1973 to 2010 (hereafter referred to as ‘SEER MM cohort’). The diagnoses of
these MMs were histologically confirmed, and MM patients 35–84 years old
were selected to match the BAP1 MM cohort. The SEER is a program of the
National Cancer Institute that gathers records of incidence, survival and prevalence of cancer from several United States state cancer registries following
strict quality rules, and covering 26% of the United States population. A total
of 10 556 MM cases were included, 8167 in male and 2389 in female (M:F
sex ratio = 3.42). The median MM survival was 8.6 months. Because available
data on survival were given in years in our BAP1 MM cohort and in months
in the SEER MM cohort, we could not directly compare survival between the
two cohorts. Nevertheless, data from the control SEER MM cohort allowed us
to compare the observed survival in the cohort of MM patients with germline
BAP1 mutations with a theoretical median survival of 1 year.
Comparison of continuous variables was performed using the t-test, the
Welch variant of t-test when the variances were significantly unequal and the
Mann–Whitney non-parametric test when the distribution of the data was not
normal. For the comparison of categorical variables the chi-squared or Fisher’s
exact test were used. Survival analysis was carried out using the Kaplan–Meier
method; the Wilcoxon test was used to compare survival curves, which is more
powerful in detecting differences early in time, rather than the log-rank test,
which is more sensitive in detecting differences late in time (35). Five-year
survival, and median survival time with 95% confidence interval (CI) were
calculated according to demographic and clinical studied factors. A multivariate stepwise Cox regression analysis was performed to evaluate independent
prognostic factors (age at diagnosis, sex, MM site, unique or multiple cancers),
and their interactions. All tests were two tailed and the significance limit was
set for P ≤ 0.05. All analyses were realized using STATA version 12.0.

Results
The characteristics of the 23 participants included in the pooled cohort
are described in Table II. Among them, 14 were female (60.9%).

The mean age at MM diagnosis was 56.3 years and median age was
55 years, ranging from 34 to 87 years. Ten patients had peritoneal
MM, 10 had pleural MM, and three had both. The histological subtype was known for only 12 patients (52.2%); all of them were of
the epithelioid subtype. Eleven patients (47.8%) are presently alive.
Thirteen patients (56.5%) had one or several other cancers in addition
to MM. There was no correlation between sex, site of cancer, mean
age at diagnosis and proportion of other cancers (Table II).
The two studied cohorts presented several significant differences:
the mean age at MM diagnosis was of 56.3 years in the BAP1 MM
cohort, and 72 years in the SEER MM cohort; the M:F ratio was
0.73:1 in the BAP1 MM cohort, and 3.42:1 in the SEER MM cohort
(P ≤ 0.0001). Moreover, the percentage of peritoneal MM was higher
in the BAP1 MM cohort (50.0%) than in the control SEER MM
cohort (14.2%, P ≤ 0.0001).
In the BAP1 MM cohort, the 5-year survival rate was 47% (95%
CI: 24–67%) compared with 6.7% (95% CI: 6.2–7.3%) in the control SEER MM cohort, and the median survival from MM diagnosis was 5 years (95% CI: 3 years; -), compared with <1 year in the
control SEER MM cohort (Figure 1). When MM survival was analyzed according to clinical characteristics of the patients with germline BAP1 mutations (Table III, Figure 2), females had a 5-year
survival of 49 versus 42% in males (P = 0.3442). Similar differences
in survival between genders were observed in the SEER MM cohort:
women had a 5-year survival of 13.3% (95% CI: 11.9–14.8%) compared with men (4.8%, 95% CI: 4.3–5.3%). In the SEER MM cohort,
survival was also better in the youngest group (median survival of
13.25 months and 5-year survival rate of 17.4% for patients younger
than 55 years; median survival of 8.11 months and 5-year survival
rate of 5.1% for patients aged 55 and older). Instead, survival was not
related to age in the BAP1 MM cohort: among those aged <55 years,
5-year survival was 45% compared with 51% among those ≥55 years
(P = 0.3658). In the BAP1 MM cohort survival was longer in patients
with a peritoneal MM (median survival of 10 years) compared with
pleural MM (median survival of 2 years, P = 0.0571). The median
survivals were comparable between peritoneal and pleural MM in
the SEER MM cohort: 8.69 and 8.55 months, respectively. Peritoneal
MM had a significantly worse 5-year survival compared with pleural
MM in the SEER MM cohort (Table III). In the BAP1 MM cohort
the presence of a second malignancy was associated with a better survival, although not significant because of the small number of patients,
compared with MM patients without a second malignancy: median
survival of 10 years, 95% CI (4 –) versus 3 years, 95% CI (1 –);
P = 0.0716.
In the multivariate analysis, only the presence of another cancer
in addition to MM (hazard ratio = 0.384, 95% CI: 0.120–1.234, P =
0.1053) was retained in the final model, but the small numbers did not
lead to a significant result. No interaction between the studied factors
(age, sex, MM site and other cancer) was significant.
Discussion
Here we tested the hypothesis that MM arising in carriers of germline BAP1 mutations have better prognosis compared with sporadic
MM. The results showed that germline BAP1 mutation carriers with
MM had roughly seven times longer survival than the control cohort,

Table I. Published germline BAP1 mutations among MM patients
References

Family

Study description

Number of MM with
BAP1 mutation

Age range
(years)

Sex M/F

Testa et al. (15)

LOU
WIS
II
III
F2
F3

Familial mesothelioma

6
4
1
1
1
4

37–66
43–58
84
47
52
34–87

2/4
1/3
0/1
1/0
0/1
1/3

Wadt et al. (20)
Wiesner et al. (18,19)

Familial melanoma
Familial melanoma
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Table II. BAP1 MM cohort patient characteristics
Variable

N

Male/female

Age at MM (years):
mean (range)

All
Sex
Female
Male
Age group (years)
34–54
55–87
Site
Pleural
Peritoneal
Both

23

9/14

56.3 (34–87)

14
9

MM first
cancer (%)

% Alive

56.5

73.7

47.8

56.4 (34–84)
56.3 (37–87)

57.1
55.6

75.0
71.4

50.0
44.4

60.0
53.8

71.4
75.0

50.0
46.1

40.0
60.0
100

87.5
62.5
66.7

40.0
50.0
66.7

10
13

4/6
5/8

—
—

10
10
3

4/6
5/5
0/3

56.2 (43–87)
58.3 (37–84)
50.7 (34–63)

>1 cancer (%)

Fig. 1. Kaplan–Meier survival curves of the BAP1 MM cohort patients (N = 23) and of the SEER MM cohort (N = 10 556). The survival curve for the control
group was based on the survival data rounded to the years.

which represented a population sample of United States MM from the
SEER database.
Compared with the SEER MM cohort, the BAP1 MM cohort had
several significant clinical differences: (i) earlier mean age at MM
diagnosis (56.3 versus 72 years); (ii) lower M:F ratio (0.73:1 versus
4:1); and (iii) higher percentage of peritoneal MM (50 versus 14.2%).
Collectively, a younger age at diagnosis, a M:F sex ratio close to 1:1
as well as a pleural:peritoneal ratio close to 1:1, are typical of MMs
developing in cohorts without occupational exposure to asbestos fibers and instead help to identify cohorts with genetic predisposition to
MM or environmentally exposed to carcinogenic mineral fibers from
early age (36). Among the individuals forming the cohort with germline BAP1 mutations and MM, none had occupational exposure to
asbestos, suggesting that either a low background amount of exposure
to mineral fibers might be sufficient to trigger MM, or alternatively
that these MM are totally unrelated to exposure to carcinogenic mineral fibers.
Since the pooled BAP1 MM cohort and the SEER MM cohort were
matched for the period of time of MM diagnosis, therapeutic options
available to patients should be similar in the two cohorts and should
not affect survival significantly. Moreover, current therapies only
extend the ~1 year MM survival by ~11 weeks (10), whereas carriers
of germline BAP1 mutations had an average survival of 5 years, an
amount of time that significantly exceeded the benefit of any available
therapy.
We tested and disproved the hypothesis that the patient characteristics in the BAP1 MM cohort might be related to the extended survival.
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MM in women has been related to better survival (13), particularly
for peritoneal MM (37). However, in the BAP1 MM cohort the 5year survival was four times better in females and nine times better in
males compared with the SEER MM group. Thus, the increased proportion of women in the BAP1 MM cohort alone could not explain the
better survival in this cohort, as males did better than females (Table
III). Similarly, the younger age of the BAP1 MM cohort was not associated with better survival as older patients in this cohort appeared
to do as well or better than younger ones, although the low number
of patients precludes studies of significance (Table III). In contrast
to the SEER MM cohort, in the BAP1 MM cohort median survival
was 10 years for peritoneal MM compared with 2 years for pleural
MM (Table III). In the general population, peritoneal MM has a very
poor prognosis with a median survival of 6–12 months from diagnosis
(38). Only recent therapies, available in specific experienced centers,
have improved the prognosis of peritoneal MM in selected patients
(39–42).
Histology was available for review for 12 MM in the germline
BAP1 mutation carrier cohort. All of them were of the epithelial
subtype a less aggressive variant compared with other histological subtypes. However, the 5-year median survival we observed in
these patients far exceeded the 1-year median survival observed in
epithelial MM (10). Interestingly, germline BAP1 mutations have
also been associated with well-differentiated papillary mesothelioma (23), a rare variant of epithelioid mesothelioma clinically
indolent with long survival (these ‘benign’ MMs were excluded
from our analysis).

Mesothelioma BAP1 carriers have 7-fold improved survival

Table III. Median and 5-year MM survival by clinical characteristics in sporadic and BAP1 mutation-carrying MM patients
MM patients with germline BAP1 mutations
Variable

N

Median survival
(95% CI)

Wilcoxon P value
between categories

5-year survival
(95% CI)

N

Median survival [months
(95% CI)]

23

5 years (3 –)

—

47% (24–67%)

10 556

<1 year [9 months (9–9)]

14
9

5 years (3 –)
4 years (1 –)

0.3442

49% (23–73%)
42% (10–71%)

2389
8167

<1 year [10 months (11–13)]
1 year [8 months (8–9)]

13.3% (11.9–14.8%)
4.8% (4.3–5.3%)

10
13

5 years (1 –)
10 years (3 –)

0.3658

45% (12–73%)
51% (20–74%)

1360
9196

1 year [13 months (13–14)]
<1 year [8 months (8–9)]

17.4% (15.3–19.6%)
5.1% (4.6–5.6%)

10
10

2 years (1 –)
10 years (1 –)

38% (10–66%)
53% (18–77%)

9247
1309

<1 year [9 months (8–9)]
<1 year [9 months (8–9)]

16.0% (13.7–18.3%)
5.2% (4.7–5.7%)

Category
All patients
Sex
Female
Male
Age
<55 years
≥55 years
Site
Pleural
Peritoneal
Both

SEER control group

3

— (5 –)

+ Other cancer
No
10
Yes
13

3 (1 –)
10 (4 –)

Pleural only versus
peritoneal only, 0.1210
Pleural only versus
peritoneal/both, 0.0571
0.0716

5-year survival (95% CI)

6.7% (6.2–7.3%)

67% (5–95%)

—

—

—

24% (4–58%)
64% (30–85%)

—
—

—
—

—
—

Fig. 2. Kaplan–Meier survival curves of the BAP1 MM cohort according to sex, age, MM site and presence of other cancers.

In summary, the clinical characteristics cannot explain the 7-fold
increased survival we observed in the cohort of MM patients with
germline BAP1 mutations.
Within this BAP1 MM cohort, both the univariate and multivariate
analyses showed a non-significant trend of improved survival in patients
with multiple cancers and/or peritoneal MM. A limitation of our study
is the small number of cases, which may prevent detecting significant
differences between the two compared cohorts. Among the 13 individuals with MM and at least one other cancer, six developed at least one
malignancy before developing MM. In these individuals, a first diagnosis of cancer might have increased the frequency of medical follow-ups
and the chances for early detection of MM. In addition, because members of families carrying germline BAP1 mutations are at high risk of
MM and other cancers, it is possible that they may seek medical evaluation earlier than the general population and be diagnosed at an earlier

stage. Early MM detection is associated with better survival; however,
only ~5% of MM are diagnosed in stage I (43). Data on the stage of
disease at diagnosis were not available in the present study. However,
although early detection in some of these patients may have contributed
to the improved prognosis, it was probably not the only factor, as the
cohort we studied includes MM patients that were diagnosed before we
discovered the BAP1 cancer syndrome, and thus before any medical
protocol for regular screening was put in place. Because early detection
is linked to improved prognosis, since 2013 we yearly screen BAP1
family members for melanoma, and most of them are also enrolled in
a biomarker clinical trial for early detection of MM and other cancers.
Acquired somatic BAP1 mutations have been reported in 22–23%
of United States MM biopsies (7,15,44) and in 61% of Japanese
MM biopsies (45). The apparent discrepancy between the United
States and Japanese results may be related to methodological or
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ethnical differences: these hypotheses are currently being investigated in a joint effort between our laboratory and some of the
Japanese investigators. However, there are no apparent distinct
clinical phenotypes for MM with somatic BAP1 mutations (44).
This is in contrast with what was observed in renal cell carcinoma
(46–49) and in uveal melanoma (50), where somatic BAP1 mutations are associated with a much more aggressive tumor phenotype
and metastases.
MM survival of 5 years or more is exceedingly rare, yet we
observed it in more than half of the MM that occurred in a cohort carrying germline BAP1 mutations. It would be an extraordinary coincidence if less aggressive cases would cluster in this way following
only a selection bias. Our data, instead, indicate that MM arising in
the context of germline BAP1 mutations is clinically less aggressive
and frequently associated with prolonged survival. This information
should be taken into account to provide appropriate genetic counseling and clinical management to MM patients with germline BAP1
mutations.
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